Therapy for early HIV infection: How far back should the pendulum swing?

Journal of Infectious Diseases

Volumn 190, Issue 6, 2004, Pages 1043-1045

  Schechter, Mauro ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; ZIDOVUDINE;

CLINICAL PRACTICE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MATHEMATICAL MODEL; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; TIME FACTORS; VIRAL LOAD;

EID: 4444242041     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422852     Document Type: Editorial

References (30)

1. Fischl MA, Richman DD, Griego MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317:185-91.
2. Friedland GH. Early treatment for HIV: the time has come. N Engl J Med 1990; 322:1000-2.
3. + cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329:297-303.
4. Hirsch MS, D'Aquila MD. Therapy for human immunodeficiency virus infections. N Engl J Med 1993; 328:1686-95.
5. Bartlett JG. Zidovudine now or later? N Engl J Med 1993; 329:351-2.
6. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 1994; 272:437-42.
7. Aboulker J-P, Swart AM. Preliminary analysis of the Concorde Trial. Lancet 1993; 341:889-90.
8. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom free HIV infection. Lancet 1994; 343:871-81.
9. Sande MA, Carpenter CCJ, Cobbs CG, et al. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993; 270:2583-9.
10. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
11. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:123-4.
12. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450-1.
13. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HFV infection in 1996: recommendations of an international panel. International AIDS Society-USA. JAMA 1996; 276:146-54.
14. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997; 277:1962-9.
15. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280:78-86.
16. Levy JA. Caution - should we be treating HIV infection early? Lancet 1998; 352:982-3.
17. Schechter M, Struchiner CJ, Harrison LH. Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? AIDS 1999; 13:97-102.
18. Schechter M, Harrison LH. Therapy of early HIV infection: time for the pendulum to swing back? AIDS Clin Care 1999; 11:79-86.
19. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
20. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy for HIV infection: updated recomendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-90.
21. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
22. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-54 (in this issue).
23. 6/L. AIDS 2002; 16:1371-81.
24. + cell strata. Ann Intern Med 2003; 138:620-6.
25. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003; 188:1659-65.
26. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy, a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
27. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-86.
28. + cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:255-64.
29. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-6.
30. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.